What company would want to own branded Copaxone if Teva and MNTA were joining forces to bring generic Copaxone to market? The answer is: nobody.
Excellent point. Thank you.
Of course, TEVA might ask themselves "Would the net benefit be in our favor were we to somehow distance ourselves from Copaxone ownership?" The way I've gathered TEVA conducts itself (like it's fighting a war, as I believe you said) I would think they've thought through a purchase scenario, with all its ramifications.
What company would want to own branded Copaxone if Teva and MNTA were joining forces to bring generic Copaxone to market? The answer is: nobody.
Teva will never be allowed to buy MNTA for the reasons you stated so this topic is moot. Regardless the assumption that nobody would want own branded Copaxone if MNTA/TEVA brought generic Copaxone to market ascribes no value to branded Copaxone under this scenario.